PMID- 27533457
OWN - NLM
STAT- MEDLINE
DCOM- 20180223
LR  - 20221207
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 36
DP  - 2016 Sep 6
TI  - Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk 
      in the Chinese population.
PG  - 58174-58180
LID - 10.18632/oncotarget.11272 [doi]
AB  - Mammalian target of rapamycin (mTOR) gene polymorphisms exert the major effects 
      on the regulation of transcriptional activity and miRNA binding or splicing, 
      which may be associated with cancer risk by affecting mTOR gene expression. 
      However, inconsistent results have been previously reported. The present study 
      evaluated the correlation between mTOR rs2536/rs2295080 polymorphisms and breast 
      cancer risk. This case-control study was performed with 560 breast cancer 
      patients and 583 healthy controls from the northwest of China. mTOR polymorphisms 
      (rs2536 and rs2295080) were genotyped by Sequenom MassARRAY. We assessed the 
      associations with odds ratios (ORs) and 95% confidence intervals (95% CIs). The 
      association between mTOR rs2536 polymorphism and breast cancer risk was 
      undetectable in our study (P > 0.05). In parallel, the significant effects were 
      observed between mTOR rs2295080 polymorphism and breast cancer risk in the 
      allele, codominant, and recessive models (P < 0.05). We detected no significant 
      correlations between rs2536 polymorphism and the clinical parameters of breast 
      cancer patients, while rs2295080 polymorphism was associated with lymph node (LN) 
      metastasis. The Crs2536Grs2295080 haplotype was correlated with a significantly 
      decreased risk of breast cancer (P < 0.05). In sum, the findings suggested that 
      mTOR rs2295080 had a protective role on breast cancer susceptibility among 
      Chinese population, while rs2536 polymorphism had no association with breast 
      cancer risk.
FAU - Zhao, Yang
AU  - Zhao Y
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Diao, Yan
AU  - Diao Y
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Wang, XiJing
AU  - Wang X
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Lin, Shuai
AU  - Lin S
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Wang, Meng
AU  - Wang M
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Kang, HuaFeng
AU  - Kang H
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Yang, PengTao
AU  - Yang P
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Dai, Cong
AU  - Dai C
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Liu, XingHan
AU  - Liu X
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Liu, Kang
AU  - Liu K
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Li, ShanLi
AU  - Li S
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Zhu, YuYao
AU  - Zhu Y
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
FAU - Dai, ZhiJun
AU  - Dai Z
AD  - Department of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi Province, PR China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Asian People/genetics
MH  - Breast/pathology
MH  - Breast Neoplasms/*genetics/pathology
MH  - Case-Control Studies
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Genotyping Techniques
MH  - Haplotypes/genetics
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Odds Ratio
MH  - Polymorphism, Single Nucleotide
MH  - TOR Serine-Threonine Kinases/*genetics
PMC - PMC5295422
OTO - NOTNLM
OT  - breast cancer
OT  - mTOR
OT  - risk
OT  - single nucleotide polymorphism
COIS- The authors declare that they have no competing interest.
EDAT- 2016/08/18 06:00
MHDA- 2018/02/24 06:00
PMCR- 2016/09/06
CRDT- 2016/08/18 06:00
PHST- 2016/06/06 00:00 [received]
PHST- 2016/07/29 00:00 [accepted]
PHST- 2016/08/18 06:00 [pubmed]
PHST- 2018/02/24 06:00 [medline]
PHST- 2016/08/18 06:00 [entrez]
PHST- 2016/09/06 00:00 [pmc-release]
AID - 11272 [pii]
AID - 10.18632/oncotarget.11272 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Sep 6;7(36):58174-58180. doi: 10.18632/oncotarget.11272.